Johnson & Johnson Innovative Medicine has strengthened its commitment in Italy, with a projected investment of €580 million over the next five years, of which €125 million will support an increase in production capacity and build capabilities for the future.

The investment is part of a strategic plan that has included a 9.2 percent investment growth each year between 2019-2023 in Italy, which is three times greater than the pharmaceutical sector average, according to a new study by The European House – Ambrosetti. Additionally, this investment has translated to a 15 percent increase in employment in Italy over the last five years to about 1,400 employees throughout the country.

In the last five years, J&J has invested nearly €50 million in Italy (+11,7 percent each year since 2019). The investments in R&D also favor a strong commitment towards scientific research in the country. In 2023, Johnson & Johnson Innovative Medicine managed 114 clinical trials and collaborated with 993 research centers in Italy, offering treatment access to more than 5,000 patients.

 

The Latina site is an important part of J&J’s global supply chain network. The site produces more than four billion tablets every year, for about 30 different products, with 97 percent of its production exported, reaching patients from worldwide.

The investment plan will enable a production capacity increase of more than 25 percent, as it includes innovative projects to support pipeline products and new production technologies, such as a Flex Line, to more efficiently handle the packaging of small production batches and a new continuous manufacturing line that will reduce total end-to-end manufacturing time and enable medicines to reach patients more quickly.

“The Johnson & Johnson site in Latina, Italy, is undergoing a significant evolution as we enhance our capabilities to serve more patients with innovative products,” said Jorge Lopez, general manager of the Johnson & Johnson Latina Plant. “It has been designated as a 4IR (Industry 4.0 site) by the World Economic Forum due to our commitment to innovation and sustainability. Times are very exciting for our site. We have a highly passionate and committed workforce, who are focused on safety, quality, and reliability as we work to provide medicines for patients around the world every single day.”